0001004878-13-000260.txt : 20130903
0001004878-13-000260.hdr.sgml : 20130902
20130903102232
ACCESSION NUMBER: 0001004878-13-000260
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20130830
ITEM INFORMATION: Other Events
FILED AS OF DATE: 20130903
DATE AS OF CHANGE: 20130903
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: CEL SCI CORP
CENTRAL INDEX KEY: 0000725363
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 840916344
STATE OF INCORPORATION: CO
FISCAL YEAR END: 0930
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11889
FILM NUMBER: 131074079
BUSINESS ADDRESS:
STREET 1: 8229 BOONE BLVD .
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
BUSINESS PHONE: 7035069460
MAIL ADDRESS:
STREET 1: 8229 BOONE BLVD.
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
FORMER COMPANY:
FORMER CONFORMED NAME: INTERLEUKIN 2 INC
DATE OF NAME CHANGE: 19880317
8-K
1
form8kitem801aug-13.txt
8-K RE NYSE COMPLIANCE
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): August 30, 2013
CEL-SCI CORPORATION
-------------------------------------
(Exact name of Registrant as specified in its charter)
Colorado 01-11889 84-0916344
-------------------- ------------------------ ----------------------
(State or other jurisdiction (Commission File No.) (IRS Employer
of incorporation) Identification No.)
8229 Boone Boulevard, Suite 802
Vienna, Virginia 22182
-------------------------------------------------
(Address of principal executive offices, including Zip Code)
Registrant's telephone number, including area code: (703) 506-9460
N/A
-----------------------------
(Former name or former address if changed since last report)
Item 8.01. Other Events.
On July 18, 2013, the Company received notice from the NYSE MKT (the
"Exchange"). indicating that the Company was not in compliance with Section
1003(a)(iv) of the Exchange's continued listing standards in the Company Guide.
The Company was afforded the opportunity to submit a plan to regain compliance,
and on August 19, 2013 the Company submitted its plan to the Exchange.
On August 30, 2013, the Exchange notified the Company that it accepted the
Company's plan of compliance and granted the Company an extension until
September 30, 2013 to regain compliance with the continued listing standards.
The Company will be subject to periodic review during the extension period.
Failure to make progress consistent with the plan or to regain compliance with
the continued listing standards by the end of the extension period could result
in the Company being delisted from the NYSE MKT.
On September 3, 2013 the Company issued a press release announcing its
receipt from the Exchange of its acceptance of the Company's plan of compliance.
The full text of this press release is attached as Exhibit 99.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: September 3, 2013 CEL-SCI CORPORATION
By: /s/ Geert R. Kersten
-------------------------------
Geert R. Kersten,
Chief Executive Officer
EX-99
2
form8kitem801ex99aug-13.txt
EXH. 99 PRESS RELEASE RE COMPLIANCE
EXHIBIT 99
CEL-SCI CORPORATION
8229 Boone Boulevard, Suite 802 COMPANY CONTACT:
Vienna, VA 22182. USA Gavin de Windt
Telephone (703) 506-9460 CEL-SCI Corporation
www.cel-sci.com (703) 506-9460
CEL-SCI ANNOUNCES THAT NYSE MKT APPROVES PLAN
Vienna, VA, September 3, 2013 - CEL-SCI Corporation (NYSE MKT: CVM) announces
that the NYSE MKT (the "Exchange") has accepted the Company's plan to bring
itself into compliance with the Exchange's continued listing standards.
The Company previously received notice from the Exchange on July 18, 2013,
indicating that the Company is not in compliance with Section 1003(a)(iv) of the
Exchange's continued listing standards in the Company Guide. The Company was
afforded the opportunity to submit a plan to regain compliance, and on August
19, 2013 the Company submitted its plan to the Exchange.
On August 30, 2013, the Exchange notified the Company that it accepted the
Company's plan of compliance and granted the Company an extension until
September 30, 2013 to regain compliance with the continued listing standards.
The Company will be subject to periodic review during the extension period.
Failure to make progress consistent with the plan or to regain compliance with
the continued listing standards by the end of the extension period could result
in the Company being delisted from the NYSE MKT.
About CEL-SCI Corporation
CEL-SCI is dedicated to research and development directed at improving the
treatment of cancer and other diseases by utilizing the immune system, the
body's natural defense system. Its lead investigational therapy is Multikine
(Leukocyte Interleukin, Injection), currently being studied in a pivotal global
Phase III clinical trial. CEL-SCI is also investigating an immunotherapy
(LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and as a
vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing)
using its LEAPS technology platform. The investigational immunotherapy
LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu,
Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned
about the possible emergence of a new more virulent hybrid virus through the
combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has
operations in Vienna, Virginia, and in/near Baltimore, Maryland.
When used in this report, the words "intends," "believes," "anticipated" and
"expects" and similar expressions are intended to identify forward-looking
statements. Such statements are subject to risks and uncertainties which could
cause actual results to differ materially from those projected. Factors that
could cause or contribute to such differences include, an inability to duplicate
the clinical results demonstrated in clinical studies, timely development of any
potential products that can be shown to be safe and effective, receiving
necessary regulatory approvals, difficulties in manufacturing any of the
Company's potential products, inability to raise the necessary capital and the
risk factors set forth from time to time in CEL-SCI Corporation's SEC filings,
including but not limited to its report on Form 10-K for the year ended
September 30, 2012. The Company undertakes no obligation to publicly release the
result of any revision to these forward-looking statements which may be made to
reflect the events or circumstances after the date hereof or to reflect the
occurrence of unanticipated events.